UTHR
Undervalued by 110.1% based on the discounted cash flow analysis.
Market cap | $19.57 Billion |
---|---|
Enterprise Value | $17.97 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $26.44 |
Beta | 0.62 |
Outstanding Shares | 45,100,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 15.71 |
---|---|
PEG | 139.14 |
Price to Sales | 6.52 |
Price to Book Ratio | 2.79 |
Enterprise Value to Revenue | 5.84 |
Enterprise Value to EBIT | 11.34 |
Enterprise Value to Net Income | 14 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...